Gonadal status and body mass index jointly determine growth hormone (GH)-releasing hormone/GH-releasing peptide synergy in healthy men

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in this randomized controlled trial publication.

Whether sex steroids modify the negative effect of BMI on secretagogue-induced GH secretion in men is not known.

The issue is important in designing GH-stimulation regimens that are relatively insensitive to both gonadal status and adiposity.

Who Took Part

PubMed indexes the participants as adults, men only.

Healthy young men were included in the study.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The study was performed at an academic medical center.

What Was Measured

PubMed files the paper under topics including Arginine, Body Mass Index, Drug Synergism, Growth Hormone-Releasing Hormone, Human Growth Hormone, Hypogonadism and Oligopeptides.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.